Episode
How Health Tech Is Personalizing Cancer Vaccines with mRNA
- Published
- Jun 19, 2026
- Duration seconds
- 471
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-digital-health-podcast-with-fexingo-wearables-diagnostics-and-health-software-7872006/episodes/how-health-tech-is-personalizing-cancer-vaccines-with-mrna/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-digital-health-podcast-with-fexingo-wearables-diagnostics-and-health-software-7872006/how-health-tech-is-personalizing-cancer-vaccines-with-mrna.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Episode 60 of The Digital Health Podcast explores how mRNA technology is being repurposed from COVID-19 vaccines to create personalized cancer immunotherapies. Lucas and Luna break down the science behind neoantigen prediction, the case of Moderna and Merck's melanoma trial showing 44% reduction in recurrence risk, and the logistical hurdles of manufacturing a custom vaccine for each patient within weeks. They discuss how AI-powered tumor sequencing enables this precision, the cost implications (around $100,000 per course), and what this means for the future of oncology. A concrete look at how digital health and genomics are converging to make individualized cancer treatment a reality. #mRNA #CancerVaccines #PersonalizedMedicine #Immunotherapy #Moderna #Merck #Melanoma #Neoantigen #TumorSequencing #AIHealth #DigitalHealth #Oncology #Biotech #Genomics #HealthcareAI #Business #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo